USFDA conducts inspection at two manufacturing facilities of Natco Pharma

28 Mar 2016 Evaluate

The United States Food & Drug Administration (USFDA) has conducted inspection at two manufacturing facilities of Natco Pharma recently. The inspection was conducted at the Active Pharmaceutical Ingredients (API) manufacturing facility at Manali, near Chennai, and the Pharmaceutical Formulations facility at Kothur, near Hyderabad, during early February and March, 2016, respectively.

The company has received 483 observations for both facilities and believes them to be of minor in nature. The company has already sent response and compliance report for these observations and believes that there would be no adverse impact to its current or future pipeline products coming from these facilities.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.



Natco Pharma Share Price

824.05 -21.15 (-2.50%)
20-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1381.00
Zydus Lifesciences 872.95
Lupin 2160.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×